Amneal Reports Q3 2026 Revenue of $863 Million, Updates Guidance
Amneal reported a GAAP net loss of $22 million and a diluted loss per share of $(0.06). Adjusted EBITDA was $207 million, with adjusted diluted EPS of $0.26.
Story updates
11:02:38 AM UTC
SquawkNews
Q3 2026 revenue was $863M, up 10% from $785M a year earlier; adjusted EBITDA rose 30% to $207M. Amneal increased full-year 2026 guidance for revenue, adjusted EBITDA and adjusted diluted EPS.Material DetailsContext by AI AnalystThis is a mid-cycle update, with reported growth alongside higher costs…
11:03:50 AM UTC
SquawkNews
Nov 03 (Reuters) - Amneal Pharmaceuticals Q3 adjusted EBITDA USD 207 million.
11:12:22 AM UTC
SquawkNews
*-- Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $0.26 per Share, vs.
Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) —— Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 —— Updating 2026 Full Year Guidance —BRIDGEWATER, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. NASDAQ:AMRX…